Deal With Regeneron Means Validation For Ocular Therapeutix

Following a strategic collaboration, option and license agreement Ocular Therapeutix Inc (NASDAQ: OCUL) announced with Regeneron Pharmaceuticals Inc (NASDAQ: REGN), BTIG said the deal provides external validation for the former's platform technology. The deduction is based on the fact that Regeneron is the leader in the ophthalmology space.

Analyst Ling Wang noted that the agreement is for developing a sustained release formulation of aflibercept for the treatment of wet age-related macular degeneration. Ocular Therapeutix stands to gain $10 million from Regeneron upon exercising the option along with milestone payments of up to $350 million and royalties on potential future product sales.

Related Link: Ocular Therapeutix Shares Charge Higher Following Collaboration Deal With Regeneron

BTIG sees the deal terms as favorable, given the potential for large upside with a back-end loaded structure.

BTIG has a Buy rating and a $18 price target on the shares of Ocular Therapeutix.

At the time of writing, shares of Ocular Therapeutix were up 15.37 percent at $7.28, and those of Regeneron were up 1.19 percent at $377.90.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!